U.S. Makes Initial Offers in Medicare Drug Price Negotiationsnews2024-02-01T18:36:19+00:00February 1st, 2024|The New York Times|
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelmnews2024-01-31T19:10:58+00:00January 31st, 2024|The New York Times|
Medicare Open Enrollment Is Starting. Here’s How to Navigate the Ad Blitz.news2023-10-14T09:01:47+00:00October 14th, 2023|The New York Times|
Drug Makers Agree to Negotiate With Medicare on Prices of 10 Medicationsnews2023-10-03T22:38:52+00:00October 3rd, 2023|The New York Times|
As Covid Infections Rise, Nursing Homes Are Still Waiting for Vaccinesnews2023-09-27T16:51:23+00:00September 27th, 2023|The New York Times|
Does Obamacare Explain Medicare’s Spending Slowdown?news2023-09-09T09:01:33+00:00September 9th, 2023|The New York Times|
A Performance Review for President Bidennews2023-09-07T16:07:32+00:00September 7th, 2023|The New York Times|
4 Arguments You Will Hear Against Medicare Drug Price Negotiationnews2023-09-06T09:01:57+00:00September 6th, 2023|The New York Times|
A Huge Threat to the U.S. Budget Has Receded. And No One Is Sure Why.news2023-09-05T12:23:43+00:00September 5th, 2023|The New York Times|
The Promise and Risk of Biden’s War on Drug Pricesnews2023-09-01T19:25:02+00:00September 1st, 2023|The New York Times|
